The alarming outbreak of the Ebola virus in 2014 underscored the critical importance of early virus detection to curb its rapid dissemination.
The unparalleled sensitivity of NBT technology holds the potential to detect the Ebola virus within 24 to 72 hours of exposure, even before individuals display symptoms. Swift identification not only expands treatment options for those exposed but also plays a pivotal role in stemming the virus’s transmission. Furthermore, the NBT Device’s lightweight design and user-friendliness position it as an indispensable tool for facilities worldwide where Ebola poses a threat, including airports, clinics, border crossings, and other relevant sites in less-developed regions.
While the biomarker for the Ebola virus remains to be identified, Ancon Medical anticipates that research could yield results in as little as three months. Once the biomarker is pinpointed, Ancon Medical’s NBT Device will emerge as a potent instrument for preventing and containing outbreaks.